中国临床药理学杂志Issue(4)：297-299,3.DOI:10.13699/j.cnki.1001-6821.2016.04.003
氯沙坦钾联合益肾化湿颗粒治疗慢性肾小球肾炎的临床疗效及安全性评价
Clinical efficacy and safety of losartan potassium combined with yishenhuashi in the treatment of chronic glomerulonephritis
摘要
Abstract
Objective To observe the clinical efficacy of losartan potas-sium particles joint yishenhuashi particles and leukotactin -1 (LKN-1), tumor necrosis factor ( TNF -α) , interleukin -13 ( IL -13 ) level changes in chronic glomerulonephritis.Methods Fifty -eight patients with chronic glomerulonephritis were randomly divided into treatment group and control group , 29 cases in each group.Control group was trea-ted with oral losartan potassium 50 mg, once a day.Treatment group was given yishenhuashi 10 mg, 3 times a day.The course of two groups was 12 weeks.Clinical efficacy , before and after treatment of leukocyte LKN-1, TNF -αand IL -13, serum creatinine ( Scr), blood urea nitrogen ( BUN) and 24 h urine protein quantification ( Up ) of varying levels were compared between two groups.Results The total efficiency of treatment group was 82.76% higher than 62.07% of control group , the difference was statistically significant ( P<0.05 ).After treatment, LKN-1, TNF-α, IL-13, Scr, BUN, former Up levels significantly decreased in both groups (P<0.05).And LKN-1, TNF-α, IL-13 and UP levels in treatment group declined more significant than the control group , the difference was statistically significant ( P<0.05 ) .No other serious adverse drug reactions such as liver and kidney dysfunction , skin rash were observed.Conclusion Losartan potassium joint yishenhuashi particles for the treatment of chronic glomerulonephritis can effectively improve the clinical efficacy and reduce serum LKN -1, TNF-αand IL-13 levels, decrease proteinuria.关键词
慢性肾小球肾炎/氯沙坦钾/益肾化湿颗粒/临床疗效/安全性Key words
chronic glomerulonephritis/losartan potassium/yishenhuashi particle/clinical efficacy/safety分类
医药卫生引用本文复制引用
周静,魏昕,曾艳,杨柳,李秋月,王瑜,罗来敏..氯沙坦钾联合益肾化湿颗粒治疗慢性肾小球肾炎的临床疗效及安全性评价[J].中国临床药理学杂志,2016,(4):297-299,3.基金项目
江西省卫生厅科技计划基金资助项目 （）
